Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 331-336

  David Neto, Elias ^a   Takaki, Kelly M ^a   Agena, Fabiana ^a   Romano, Paschoalina ^a   Sumita, Nairo M ^a   Mendes, Maria E ^a   Neri, Leticia Aparecida Lopes ^a   Nahas, William C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunosuppression; Mycophenolic acid; Pharmacokinetic; Proton pump inhibitor; Renal transplantation

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; OMEPRAZOLE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861229577     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824d6e8e     Document Type: Article

References (22)

1. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083. (Pubitemid 38868597)
2. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503. (Pubitemid 47566324)
3. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30:46-51. (Pubitemid 351161098)
4. Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28:605-611.
5. Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49:1196-1201.
6. Kiberd BA, Wrobel M, Dandavino R, et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33:120-123.
7. Logan AJ, Morris-Stiff GJ, Bowrey DJ, et al. Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. Clin Transplant. 2002;16:163-167. (Pubitemid 34746391)
8. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31.
9. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9:1650-1656.
10. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49:2061-2067.
11. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994. (Pubitemid 40571246)
12. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154. (Pubitemid 38373108)
13. Pereira L, Castro M, Ventura C, et al. The modify study in renal transplantation (modification of doses to improve function through the years). Am J Transplant. 2005;11(suppl 5):466.
14. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2011;5:341-358.
15. David-Neto E. Mycophenolic acid (MPA) pharmacokinetics (PK) in stable renal transplanted (RTX) children. Am J Transpl. 2002;2(suppl 3): 192. Abstract 214.
16. David-Neto E, Pereira LM, Kakehashi E, et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant. 2005;19:19-25. (Pubitemid 40227847)
17. Van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
18. Tonshoff B, David-Neto E, Ettenger R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev. 2011;25:78-89.
19. Lidgate D, Brandl M, Holper M, et al. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm. 2002;28:1275-1283. (Pubitemid 35416655)
20. Gaston RS, Kaplan B, Shah T, et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009;9:1607-1619.
21. Gedda K, Scott D, Besancon M, et al. Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology. 1995;109:1134-1141.
22. Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep. 2010;12:437-447.